Biosynex SA

As of December 31, 2025, Biosynex SA carries a market capitalization of 10.69M, placing it among publicly traded companies globally. Its enterprise value stands at 63.88M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Biosynex SA's next confirmed earnings release is scheduled for March 3, 2027.

As of December 31, 2025, Biosynex SA has 18.43M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Biosynex SA maintains a current ratio of 1.94, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Biosynex SA's stock has gained approximately 23.94% over the past 52 weeks. The 50-day moving average sits at 0.90, while the 200-day moving average is 0.91.

As of December 31, 2025, Biosynex SA holds 8.46M in cash and equivalents against 61.65M in total debt, resulting in a net debt position of 53.19M. Total book value stands at 34.95M, with working capital of 26.97M providing operational flexibility.

Biosynex SA's most recent stock split took place on January 24, 2025.